Peer-Reviewed Publication: Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3
As the search for reliable biomarkers in neurodegenerative diseases continues, researchers are working to better understand how disease-related proteins can support diagnosis, monitoring, and future treatment development. A newly published study in Movement Disorders investigates polyglutamine-expanded ATXN3 in Spinocerebellar Ataxia Type 3 (SCA3), one of the most common inherited ataxias.
The study, co-authored by Rana Hanna Al-Shaikh, MD, Senior Medical Monitor at P95 Julius Clinical, contributes to the growing body of evidence supporting biomarker research in rare neurological disorders. The findings offer valuable perspectives for researchers and clinicians working to advance the understanding and management of SCA3.
Related resources
Peer Reviewed Publication: LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis
LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis: A Post-hoc Analysis of the FRANCIS Randomized TrialPatients with rheumatoid arthritis (RA) face an increased risk of cardiovascular disease, driven by a complex in...
Fact Sheet: MASH Clinical Development
MASH CRO Expertise for Complex Clinical Trials As MASH clinical development continues to evolve, sponsors face increasing challenges in patient identification, complex eligibility criteria, high screening failure rates, and competition for experi...
Case Study: Delivering Early Enrollment Against Aggressive Timelines in a Phase II Parkinson’s Disease Study
How a Site-Centric Delivery Model Accelerated Study Start-Up When a Phase II Parkinson’s disease study faced aggressive start-up and enrollment targets, the study team was tasked with achieving first patient consent within just eight weeks of f...